URGN UroGen Pharma Ltd.

30.45
-0.55  -2%
Previous Close 31
Open 30.78
Price To Book 7.02
Market Cap 638,828,211
Shares 20,979,580
Volume 316,921
Short Ratio
Av. Daily Volume 187,063
Stock charts supplied by TradingView

NewsSee all news

  1. UroGen to Present at 38th Annual J.P. Morgan Healthcare Conference

    UroGen Pharma Ltd. (NASDAQ:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that Liz

  2. UroGen Pharma Announces FDA Filing Acceptance and Priority Review of U.S. New Drug Application (NDA) for UGN-101

    Potential for UGN 101 to be First Non-Surgical Therapy for the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC) UroGen Pharma Ltd. (NASDAQ:URGN) today announced the U.S. Food and Drug Administration (FDA)

  3. UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced the grants of inducement restricted stock units ("RSUs") to five

  4. UroGen to Present at November 2019 Investor Conferences

    UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will participate in fireside chats at the following

  5. UroGen Pharma Reports Third Quarter 2019 Financial Results and Recent Corporate Developments

    Completed Submission of New Drug Application (NDA) to U.S. FDA for UGN-101 in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Exclusive Worldwide License Agreement with Agenus to Advance Treatment of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial ongoing.
RTGel in combination with BOTOX
Overactive Bladder (OAB)
Phase 2a planned for 1H 2019.
Vesimune
Carcinoma In-Situ (CIS)
Phase 3 trial planned for 2020.
VesiGel UGN-102
Low grade non-muscle invasive bladder cancer (LG-NMIBC)
PDUFA date under priority review April 18, 2020.
MitoGel - UGN-101
Urothelial Carcinoma

Latest News

  1. UroGen to Present at 38th Annual J.P. Morgan Healthcare Conference

    UroGen Pharma Ltd. (NASDAQ:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that Liz

  2. UroGen Pharma Announces FDA Filing Acceptance and Priority Review of U.S. New Drug Application (NDA) for UGN-101

    Potential for UGN 101 to be First Non-Surgical Therapy for the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC) UroGen Pharma Ltd. (NASDAQ:URGN) today announced the U.S. Food and Drug Administration (FDA)

  3. UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced the grants of inducement restricted stock units ("RSUs") to five

  4. UroGen to Present at November 2019 Investor Conferences

    UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will participate in fireside chats at the following

  5. UroGen Pharma Reports Third Quarter 2019 Financial Results and Recent Corporate Developments

    Completed Submission of New Drug Application (NDA) to U.S. FDA for UGN-101 in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Exclusive Worldwide License Agreement with Agenus to Advance Treatment of

  6. UroGen Pharma Announces Exclusive License Agreement with Agenus Inc to Advance Treatment of Urinary Tract Cancers

    UroGen to Develop and Commercialize Zalifrelimab (AGEN1884, anti-CTLA-4 antibody) with UGN-201 for High-Grade Non-Muscle Invasive Bladder Cancer UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical

  7. UroGen Pharma to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

    Conference Call and Webcast Scheduled for Tuesday, November 12, 2019 at 8:30 AM ET UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report third quarter 2019 financial results on Tuesday, November 12,

  8. UroGen To Present at October 2019 Investor Conference

    UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will present at the following conference in

  9. UroGen Investor Day Details Positive Clinical Updates, UGN-101 Launch Preparedness, and Pipeline Advances

    UGN-101 and UGN-102 Demonstrate Positive Clinical Data in Low-Grade Upper Tract Urothelial Cancer (LG UTUC) and Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC) UGN-101 Final Data Modules for NDA Submission

  10. UroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer

    UGN-101: Consistent Complete Response (CR) Rate of 59 Percent in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Durability of Response Determined to be 89 Percent at Six Months and 84 Percent at 12

  11. UroGen To Host Investor Day on September 24, 2019 Spotlighting Clinical Development Updates and UGN-101 Launch Readiness

    Company to Also Participate in September Investor Conferences UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced

  12. UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced the grants of inducement restricted stock units ("RSUs") to 15